Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
kalitERA
NCT07827573Phase 3Recruiting
- Sponsor
- Roche
- Start
- Dec 2026
- Primary completion
- Nov 2028
- Countries
- 1
01
Overview
A Phase 3 trial of giredestrant in breast cancer, sponsored by Roche. Planned start Dec 2026; status: recruiting.
02
Drugs
giredestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07827573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07827573.